Targeted nanogels: A versatile platform for drug delivery to tumors

Molecular Cancer Therapeutics

Volumn 10, Issue 6, 2011, Pages 972-982

  Murphy, Eric A ^a   Majeti, Bharat K ^a   Mukthavaram, Rajesh ^a   Acevedo, Lisette M ^a   Barnes, Leo A ^a   Cheresh, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BOSUTINIB; DASATINIB; DOCETAXEL; HUMAN SERUM ALBUMIN; NANOCARRIER; NANOGEL; PACLITAXEL; SORAFENIB; SUNITINIB; TANESPIMYCIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CROSS LINKING; DOSE RESPONSE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STORAGE; DRUG TARGETING; FREEZE DRYING; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; FREEZE DRYING; HUMANS; INTEGRIN ALPHAVBETA3; LIPIDS; MICE; MICE, NUDE; PACLITAXEL; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; POLYMERS; TAXOIDS;

EID: 79958739996     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0729     Document Type: Article

References (43)

1. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
2. Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 1995;13:914-20.
3. Gabizon A, Goren D, Cohen R, Barenholz Y. Development of liposomal anthracyclines: from basics to clinical applications. J Control Release 1998;53:275-9. (Pubitemid 28218710)
4. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001;46:169-85.
5. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophorfree, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002;8:1038-44. (Pubitemid 34517637)
6. Gradishar W, Krasnojon D, Cheporov S, Makhson A, Manikhas G, Clawson A, et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25:1032.
7. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009;100:572-9.
8. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006;16:175-83. (Pubitemid 44358991)
9. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85.
10. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92. (Pubitemid 17221789)
11. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993;1151:201-15. (Pubitemid 23283973)
12. Lasic DD, Frederik PM, Stuart MC, Barenholz Y, McIntosh TJ. Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett 1992;312:255-8.
13. Bianco A, Kostarelos K, Prato M. Opportunities and challenges of carbon-based nanomaterials for cancer therapy. Expert Opin Drug Deliv 2008;5:331-42. (Pubitemid 351454382)
14. Soman NR, Baldwin SL, Hu G, Marsh JN, Lanza GM, Heuser JE, et al. Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest 2009;119:2830-42.
15. Matsumura Y. Preclinical and clinical studies of anticancer drug-incorporated polymeric micelles. J Drug Target 2007;15:507-17. (Pubitemid 47209051)
16. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-909.
17. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91.
18. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003;17:3112-26. (Pubitemid 38040774)
19. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A 2008;105:9343-8.
20. Van Thienen TG, Horkay F, Braeckmans K, Stubbe BG, Demeester J, De Smedt SC. Influence of free chains on the swelling pressure of PEG-HEMA and dex-HEMA hydrogels. Int J Pharm 2007;337:31-9. (Pubitemid 46756033)
21. Dai X, Su Z, Liu JO. An improved synthesis of a selective [alpha]v[beta]3-integrin antagonist cyclo(-RGDfK-). Tetrahedron Lett 2000;41:6295-8.
22. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-9.
23. Grimm J, Potthast A, Wunder A, Moore A. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer 2003;106:806-11. (Pubitemid 36993405)
24. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004;10:7775-84. (Pubitemid 39557543)
25. Hensarling RM, Doughty VA, Chan JW, Patton DL. "Clicking" polymer brushes with thiol-yne chemistry: indoors and out. J Am Chem Soc 2009;131:14673-5.
26. Haubner R, Gratias R, Diefenbach B, Goodman SL, Jonczyk A, Kessler H. Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ antagonists. J Am Chem Soc 1996;118:7461-72. (Pubitemid 26279800)
27. Schiffelers RM, Koning GA, ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003;91:115-22. (Pubitemid 37288882)
28. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 1997;15:542-6. (Pubitemid 27251571)
29. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009;16:510-20.
30. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53. (Pubitemid 43949942)
31. Von Hoff D, Borad M, Ramanathan R, Smith L, Drengler R, Wood T, et al. Promising clinical activity of a NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer. 99th AACR Annual Meeting; 2008. San Diego, CA; 2008. p. Abstract 4179.
32. Chan S, Gerson B. Free drug monitoring. Clin Lab Med 1987;7:279-87. (Pubitemid 17113979)
33. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008;60:1638-49.
34. Kim JO, Sahay G, Kabanov AV, Bronich TK. Polymeric micelles with ionic cores containing biodegradable cross-links for delivery of chemotherapeutic agents. Biomacromolecules 2010;11:919-26.
35. Chavanpatil MD, Khdair A, Patil Y, Handa H, Mao G, Panyam J. Polymer-surfactant nanoparticles for sustained release of water-soluble drugs. J Pharm Sci 2007;96:3379-89.
36. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-72. (Pubitemid 41112931)
37. Valencia PM, Basto PA, Zhang L, Rhee M, Langer R, Farokhzad OC, et al. Single-step assembly of homogenous lipid-polymeric and lipidquantum dot nanoparticles enabled by microfluidic rapid mixing. ACS Nano 2010;4:1671-9.
38. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009;5:73-82.
39. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7. (Pubitemid 34734217)
40. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6. (Pubitemid 28237365)
41. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, et al. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63:5838-43. (Pubitemid 37187482)
42. Ricci F, Kern SE, Hruban RH, Iacobuzio-Donahue CA. Stromal responses to carcinomas of the pancreas: juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biol Ther 2005;4:302-7. (Pubitemid 41351290)
43. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.